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Ulrike Bacher,1 Julie-An Talano,2 Michael R. Bishop3Acute myeloid leukemia and myelodysplastic syndromes are the most common indications for allogeneic
hematopoietic cell transplantation. Although this treatment can be curative, even in advanced disease, treat-
ment failure is commonly manifested by relapse of disease, for which treatment is successful in only a minority
of patients. There is a necessity for new strategies for prevention of posttransplantation relapse through
early disease detection and intervention in order to improve patient outcomes. Detection of minimal
residual disease in posttransplantation surveillance is felt to be a necessary component of any strategy. In
chronic myeloid leukemia, assessment of the BCR-ABL1 load by quantitative real-time PCR provides an
optimal guideline for posttransplantation therapeutic decisions, but in patients with acute myeloid leukemia
or myelodysplastic syndromes, the situation is more complex because of the genetic heterogeneity of these
disorders. Past strategies for relapse prevention have focused on use of donor lymphocyte infusions with
variable success. Peritransplantation and maintenance therapies (eg, azacitidine) are under current investiga-
tion. This review summarizes the current status of minimal residual disease monitoring and prevention strat-
egies for both pediatric and adult patients with myeloid malignancies in the transplantation setting and
discusses perspectives for further improvement.
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Monitoring, Prevention, Molecular markersINTRODUCTION
Allogeneic hematopoietic cell transplantation
(HCT) is often indicated as part of the initial treatment
of patients with poor-risk acute myeloid leukemia
(AML) and myelodysplastic syndromes (MDS), and
it is the only curative option in those with advanced
disease. Recent improvements in treatment plans and
supportive care have reduced treatment-related mor-
tality, and disease relapse has now emerged as the prin-
ciple reason for treatment failure after transplantation.
In patients with myeloid malignancies, therapeutic
strategies aim to select poor-risk patients for alloge-
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6/j.bbmt.2011.10.028and adverse cytogenetic risk, groups have a significant
survival benefit from allogeneic HCT in first remis-
sion. In MDS, patients in intermediate-2 and high-
risk International Prostate Symptom Score groups,
immediate transplantation was associated with maxi-
mal life expectancy. Chronic myeloid leukemia
(CML) became a domain of tyrosine kinase inhibitor
(TKI) therapy, and allogeneic HCT has remained an
up-front strategy only for patients whose disease is
resistant to TKI treatment or advanced disease beyond
first the chronic phase. Therefore, patients with AML
or MDS who are candidates for allogeneic HCT have
a higher relapse risk in the posttransplantation period.
Indeed, reports from the Center for International
Blood andMarrowTransplant Research demonstrated
relapse rates following myeloablative conditioning
regimens of over 60% for patients with active at the
time of transplantation.
As reviewed in a previous workshop report [2], risk
factors for relapse after transplantation vary with the
diagnosis of the underlying malignancy, but patients
who underwent transplantation while not in remission
are at especially high risk for posttransplantation recur-
rence independent of diagnosis. Factors that influence
the duration of survival after relapse include age, perfor-
mance status, comorbidities, remission duration, tumor
Biol Blood Marrow Transplant 18:S62-S73, 2012 S63Monitoring and Preventing AML/MDS Relapse after Transplantburden at relapse, and presence of mixed chimerism.
With rare exception, however, posttransplantation re-
lapse is ultimately fatal. Consequently, development of
new strategies to prevent relapse is imperative if survival
of patients who underwent transplantation is to im-
prove.STRATEGIES FOR MONITORING MINIMAL
RESIDUAL DISEASE IN THE PRE- AND
POSTTRANSPLANTATION PERIOD IN
PATIENTS WITH MYELOID MALIGNANCIES
Traditionally, the detection of impending relapse
in the posttransplantation period had been based on
donor chimerism analysis, but the lack of specificity
remains a problem. Therefore, interest focused on
the introduction of minimal residual disease (MRD)
diagnostics in the posttransplantation care of patients
with myeloid malignancies aiming to detect an in-
crease of the leukemic cells at the earliest possible
time [3]. For patients with CML, MRD monitoring
of the BCR-ABL1 load is well established in the
conservative [4] as in the transplantation context [5],
but in AML and MDS, the development of posttrans-
plantationMRD strategies is more complex because of
the genetic heterogeneity of these disorders. Never-
theless, for some genetic subtypes, for example, recip-
rocal translocations [6] or NPM1-mutated AML [7,8],
MRD monitoring in the posttransplantation period
has already been realized. It further remains to be
clarified whether the MRD status at the time of
HCT is prognostically relevant in patients who
achieved complete hematologic remission. This
section summarizes the current status of strategies
for MRD measurement (Table 1) for adult patients
with AML, MDS, or CML in the pre- and posttrans-
plantation period and discusses perspectives for fur-
ther improvement.
Diagnostic Techniques
Mutation detection in hematologic malignancies
relies on variousmodifications of the classical polymer-
ase chain reaction (PCR) technique. Reciprocal gene
fusions are detected by reverse transcription PCR
(RT-PCR) following RNA extraction and cDNA syn-
thesis. Real-time PCR enables the assessment of PCR
amplification in the sample based on the detection of
fluorescent dyes or fluorescent-tagged DNA probes
(sensitivity: 1024-1025). Confirmation of themutations
and further analysis mostly relies on direct Sanger
sequencing using dye terminators. This might change
rapidly with the advent of high-throughput sequencing
[9]. At present, quantitative real-time PCR (RQ-PCR)
and nested PCR are the most useful methods for
MRD assessment. Nested PCR is done by two
consecutive PCR reactions with two different primerpairs targeting the region of interest, which results in
high sensitivity (1026) and highest specificity. Immu-
nophenotyping by multiparametric flow cytometry,
which is able to combine up to 10 different fluoro-
chromes, is less sensitive (1023-1024) compared with
real-time PCR, but leukemia-associated immunophe-
notypes (which are characterized, eg, by cross-lineage
expression of antigens) are detectable in virtually all
AML patients. Interphase fluorescence in situ hybrid-
ization relies on fluorescence-tagged probes with spec-
ificity for distinct gene loci or for certain centromere
regions. A total of 100 to 200 interphase nuclei can
easily be evaluated for MRD purposes in patients
with previously known cytogenetic alterations.
AML
Cytogenetic analysis detects prognostically rele-
vant alterations in 55% of de novo AML patients,
and molecular methods reveal genetic alterations in
the vast majority of normal karyotype cases. Mutations
of the NPM1 gene (in 55% of normal karyotype
AML cases) are prognostically favorable in case of iso-
lated occurrence, but coincidence with the adverse
FLT3-ITDs considerably worsens prognosis. Other
alterations observed at lower frequencies in normal
karyotype AML are the FLT3-TKD, the adverse
MLL-PTDs, and CEBPA gene mutations, which are
prognostically favorable in case of biallelic occurrence.
The panel of known molecular markers in AML is
becoming more complex: Mutations of the TET2
(‘‘tet oncogene familymember 2’’) gene were identified
in 12% to 25% of AML cases [10], and mutations of
the isocitrate dehydrogenase genes (IDH-1 and
IDH2) occur in 15% [11]. These markers seem to
be prognostically relevant in distinct molecular sub-
groups of normal karyotype AML.
Pretransplantation MRD in AML
Walter et al. [12] investigated 99 AML patients
receiving myeloablative HCT in first complete remis-
sion (CR) by 10-color flow cytometry before transplan-
tation. MRD-positive patients had lower 2-year
estimates of overall survival (OS) (30.2% versus
76.6%) and higher 2-year estimates of relapse (64.9%
versus 17.6%), compared withMRD-negative patients.
After adjustment for other prognostically relevant
parameters, a positive MRD status pre-HCT was sig-
nificantly associated with increased overall mortality
and relapse relative to MRD-negative HCT. Studying
68 patients with AML/MDS receiving allogeneic
HCT, Kebriaei et al. [13] found a trend toward im-
proved outcomes in patients in cytogenetic remission
compared with those with residual cytogenetic abnor-
malities at the time of HCT. Patients with cytomor-
phologic and cytogenetic remission had a median
progression-free survival of 7.8 months compared
Table 1. Methods for Monitoring Minimal Residual Disease (MRD) in Patients with CML, AML, and MS in the Posttransplantation Period
Donor Chimerism Analysis Molecular Genetics Immunophenotyping Additional Methods Perspectives
Sensitivity  Real-time PCR: 1024-1025
 STR-PCR: 1023
 XY-FISH: 1022
 Real-time PCR: 1024-1025
 Nested PCR: 1024-1026
Multiparametric flow cytometry:
1023-1024
 Chromosome banding
analysis: 1021
 Interphase FISH: 1022
Introduction of high-throughput
sequencing for MRD diagnostics
CML  May be restricted to the early engraftment period
 Higher specificity of BCR-ABL1 for relapse detection
ELN response criteria:
MMR: BCR-ABL1/ABL1 #0.1%
CMR: negativity of RQ-PCR and/or nested
PCR (2)
KD mutation screening: DHPLC/sequencing
Monitoring of patients with a history of
accelerated/blast phase
Chromosomal banding:
 cytogenetic response
(% Phi+ metaphases)
 clonal evolution
Interphase FISH:
 BCR-ABL1
 ACAs
Introduction of more sensitive
techniques for BCR-ABL1
monitoring and for the
detection of KD mutations
AML  Central position for relapse diagnostics
 CD34+ selected chimerism may increase sensitivity
 Kinetics should be considered in case of mixed
chimerism
Molecular mutations:
Reciprocal translocations
 RUNX1-RUNX1T1
 CBFB-MYH11
 MLL rearrangements
>> real-time/nested RT-PCR
NPM1mut: RQ-PCR
Gene expression: WT1 (RQ-PCR)
Applicability post-HCT has been shown
in studies
Precondition: definition of leukemia-
associated immunophenotype at
diagnosis of the AML
Interphase FISH:
in case of cytogenetic
alterations at diagnosis
 Numerical/structural
gains/losses
 Balanced/unbalanced
rearrangements
Expansion of the molecular MRD
marker panel:
 RUNX1
 RAS
 MLL-PTD
 FLT3-ITD
Definition of cutoff levels for
therapeutic intervention
MDS In many cases, the only option for sensitive follow-up
diagnostics (see AML)
 MRD measurement based on molecular
mutations not yet established
 Gene expression: WT1 (RQ-PCR)
Monitoring for MDS with blast increase (see AML) Development of a molecular
MRD panel
 RUNX1
 TET2
 ASXL1
Phi+ indicates Philadelphia positive; RQ-PCR, quantitative real-time PCR; FISH, fluorescence in situ hybridization; ELN, European LeukemiaNet; ACAs, additional chromosomal alterations; BP, blast phase; MMR,major
molecular response; CMR, complete molecular response; KD, kinase domain.
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Biol Blood Marrow Transplant 18:S62-S73, 2012 S65Monitoring and Preventing AML/MDS Relapse after Transplantwith\3 months for those with remaining cytogenetic
abnormalities or at cytomorphologic relapse at the
time of HCT.
Posttransplantation MRD in AML
In the conservative treatment setting of AML,
many MRD studies confirmed the potential of real-
time PCR to predict the relapse risk in patients with
reciprocal rearrangements. Some studies investigated
the potential of molecular MRD monitoring for
patients with reciprocal rearrangements also in the
posttransplantation period. Elmaacagli et al. [6]
monitored the CBFB-MYH11 fusion transcript by
RT-PCR in 10 patients with inv(16)/CBFB-MYH11-
positive AML after allogeneic or autologous HCT.
The CBFB-MYH11 transcript was not detectable in
six of seven patients who were in remission after allo-
geneic HCT, whereas the two patients who relapsed
after autologous HCT were CBFB-MYH11-positive
at 3 months posttransplantation. Schnittger et al. [8]
performed NPM1 mutation measurement in 252
AML patients with a positive mutation status by
RQ-PCR (including recurrent disease after HCT).
Relapses were predictable because of an NPM1
mutation level (%NPM1/ABL1) increase of $1 log
or because of an insufficient molecular response to
chemotherapy. For samples after allogeneic HCT,
the MRD levels at later intervals posttransplantation
(at 2-4 and 4-12 months) were prognostically relevant.
No other parameters but the molecular MRD status
and age were significant for event-free survival (EFS)
in the allotransplantation subgroup. Measurement of
aberrant gene expression, for example, ofWT1 (Wilms
tumor suppressor), may be an alternative to predict the
risk of posttransplantation relapse. Candoni et al. [14]
performed serial RQ-PCR measurement of WT1
expression in 25 transplantation recipients with
AML. All but one patient, who maintained complete
cytomorphologic remission post-HCT, displayed
a persistently lowWT1 copy number. Patients who re-
ceived HCT with active disease obtaining a sustained
complete cytomorphologic remission showed decrease
of the WT1 levels to normal range within the first 2
months post-HCT and remained constantly low. In
contrast, patients who relapsed after HCT had
a highWT1 copy number before the cytomorphologic
relapse, and in 50% of these cases, an increase of
WT1 expression was documented before molecular
chimerism was decreasing. In the study from Diez-
Campelo et al. [15], 41 transplantation recipients
with AML or MDS underwent MRD monitoring by
immunophenotyping. Separated by a threshold of
1023 leukemia cells at 100 days posttransplantation,
low-level MRD patients, compared with high-level
MRD, showed a higher 4-year OS rate of 73% versus
25% (P 5 .002) and a higher 4-year EFS rate of 74%
versus 17% (P 5 .01) (Figure 1A) [15].MDS
Cytogenetic alterations are detectable inmore than
50% of patients with MDS. In a large study including
2,124 MDS patients, .680 different cytogenetic cate-
gories were identified by chromosome banding analysis
[16]. Beyond the cytogenetic heterogeneity, MDS
presents as a highly heterogeneous disorder under
molecular aspects. Thol et al. [17] found mutations of
the ASXL1 (Additional sex comb-like 1) gene in
20.7% of MDS cases that were prognostically adverse.
Intrageneicmutations of theRUNX1 gene were identi-
fied in 5% to 22%of advancedMDScases [18]. Around
12% to 25% of MDS cases were observed with muta-
tions of heterogeneous structure and localization
affecting the TET2 gene [19], but their prognostic
impact has to be clarified [20]. Advanced MDS cases
may be positive for FLT3-ITDs,MLL-PTDs, NPM1,
or RAS mutations. Bejar et al. [21] performed next-
generation sequencing and mass-spectrometry– based
genotyping in 439MDS patients. Somatic point muta-
tions were identified in 18 different genes, and 51% of
all patients had at least one somatic point mutation.
Mutations of the TP53, EZH2, ETV6, RUNX1, and
ASXL1 genes had an independent adverse prognostic
impact, but none of thesemarkers has so far been incor-
porated in MRD strategies in MDS.
Most studies investigating posttransplantation
MRD in MDS focused on WT1 gene expression.
WT1 expression had been observed to increase in
patients with MDS during leukemic transformation,
whereas effective chemotherapy or HCT was followed
by decrease of WT1 expression [22]. Lange et al. [23]
investigated 88 patients with MDS or AML after
reduced-intensity conditioning (RIC)-HCT. Patients
were monitored in the posttransplantation period
combining fluorescence in situ hybridization for
previously known cytogenetic alterations, different
chimerism techniques, and real-time PCR measure-
ment ofWT1 expression. Unsorted donor chimerism,
CD341 selected donor chimerism, and WT1 expres-
sion were each significant predictors of relapse with
sensitivities up to 79% and specificities up to 91%. Re-
lapse within the next 28 days could be almost entirely
excluded in patients who neither showed significant
decrease of CD341 selected donor chimerism nor
WT1 transcript levels beyond a certain level. Thus,
WT1 expression levels and serial measurement of
CD341 selected donor chimerism were able to predict
relapse in stem cell recipients with MDS or AML
(Figure 1A).CML
The European LeukemiaNet introduced clear cri-
teria for defining the hematologic, cytogenetic, and
molecular response of patients with CML to tyrosine
kinase inhibitor treatment [4,24]. The different
Figure 1. (A) Diagnostic strategies for MRD assessment in the transplantation setting in patients with acute myeloid leukemia (AML) and myelodys-
plastic syndromes (MDS). I-FISH, interphase fluorescence in situ hybridization; RT-PCR, reverse transcription PCR; RQ-PCR, quantitative real-time PCR;
mol., molecular; num., numerical; struct., structural. (B) Diagnostic strategies for MRD assessment in the transplantation setting in patients with chronic
myeloid leukemia (CML). CHR, complete hematologic remission; TC, thrombocytes; GP, granulopoiesis; 1Phi, additional Philadelphia chromosome;
i(17q), isochromosome of 17q; CCgR, complete cytogenetic response; PCgR, partial; mCgR, minor; minCgR, minimal; noCgR, no cytogenetic response;
MMR, major molecular response; CMR, complete molecular response; KD, kinase domain.
S66 Biol Blood Marrow Transplant 18:S62-S73, 2012U. Bacher et al.response categories (‘‘optimal response,’’ ‘‘suboptimal
response,’’ ‘‘failure’’) to TKIs provide the basis for
the continuation of therapy. For quantitative BCR-
ABL1 assessment by real-time PCR, a control gene
such as ABL1 should be used. A ‘‘major molecular re-
sponse’’ is defined by a BCR-ABL1/ABL1 ratio #0.1,
‘‘complete molecular response’’ by negativity of
RQ-PCR and/or nested PCR for BCR-ABL1 in two
consecutive checks. ‘‘Complete cytogenetic response’’
means complete eradication of Philadelphia-positive
metaphases [4] (Figure 1B). HCT should be consid-
ered in all cases that experience failure on second-
line TKIs and as well in patients with accelerated or
blast phase. A suboptimal response to second- genera-
tion TKIs is also an indication for allogeneic HCT,
depending on the individual transplantation risk [24].
Addressing the posttransplantation period, Asnafi
et al. [25] performed BCR-ABL1 measurement by
RQ-PCR in 38 stem cell recipients with CML at day
100. Patients in the high-level MRD group (BCR-
ABL1/ABL1 ratio $1024) had a relapse incidence of
79% compared with 29% in the low-level/negativeMRDgroup (P5 .009). Kaeda et al. [5] performed a se-
rial investigation in 243 patients with CML after HCT
by quantitative RT-PCR for BCR-ABL1. The proba-
bility of relapse was higher in patients with persistent
low-level disease compared with patients with fluctuat-
ing low-level disease or persistently BCR-ABL1
negative patients (30.0% versus 20.8% versus 2.7%;
P 5 .009). This illustrates the prognostic potential of
serial BCR-ABL1 measurement in transplantation
recipients with CML.PREVENTION OF RELAPSE FOLLOWING
ALLOGENEIC HCT IN PEDIATRIC PATIENTS
WITH MYELOID MALIGNANCIES
Over the past decades, the cure rate of childhood
AML up front with chemotherapy alone has mark-
edly improved with 3-year EFS and OS reported
as high as 62% to 63% and 71% to 76%, respec-
tively, in most recent papers [26,27]. This can be
attributed to the stratification of risk groups and
Figure 1. (continued).
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with advancements in supportive care. However,
those patients who undergo HCT for poor-risk
AML, MDS, or AML in CR2 and beyond still
have a 30% risk of relapse of their disease posttrans-
plantation. The relapse rate has remained relatively
stagnant over the past 30 years. Novel strategies to
reduce the relapse rate post-HCT are desperately
needed in pediatrics. Particularly optimizing the
eradication of leukemic stem cell clones before
transplantation and enhancing the graft-versus-
leukemia (GVL) effect posttransplantation are areas
of interest. This section will focus on current and fu-
ture strategies under investigation in pediatric pa-
tients.Identification of High-Risk Patients before
Transplantation
With the emerging data regarding the impact of
minimal residual disease and outcomes, identifying
the poor-risk patients by the levels of MRD and offer-
ing them novel therapies pre- and/or post-HCT or as
part of the transplantation conditioning regimen may
lower the relapse rate. Various groups have looked at
the levels of MRD at different time points in pediatric
AML. In general, patients with high levels of MRD af-
ter induction, beforeHCT, or at day1100 post-HCT,
all have worse outcomes compared with patients who
have low or undetectable levels [12,15,28]. The
method of detection and the definition of levels of
MRD vary from study to study, and therefore one
S68 Biol Blood Marrow Transplant 18:S62-S73, 2012U. Bacher et al.must be cautious in comparing and interpreting the
data. Rubnitz et al. [26] performed a clinical trial in
232 pediatric patients that employed risk-adapted
therapy based on levels of MRD for de novo AML.
When evaluating the high-risk patients with MRD
.1% after induction 1, OS was better among those
who underwent HCT compared with those who did
not (43% versus 21%). Therefore, HCToffered a ben-
efit to these high-risk patients; however, the survival
rates are still dismal. Currently, there is a Pediatric
Blood and Marrow Transplant Consortium Protocol
evaluating MRD in HCT pediatric patients pre- and
post-HCT for hematologic malignancies. These data
will be helpful in designing future therapeutic clinical
trials.
Optimizing Graft Source to Lower Relapse Risk
In retrospective studies performed at the Univer-
sity of Minnesota and Fred Hutchinson Cancer
Research Center, investigators have found that utiliz-
ing double umbilical cord blood as a graft source for
HCT has led to a lower relapse risk in leukemias
[29,30]. Verneris et al. [29] analyzed 177 patients
who underwent myleoablative transplantation for leu-
kemias using either a single or double unrelated umbil-
ical cord. In the univariate analysis, there was a lower
risk for relapse (19%) in double-unit transplantation
recipients versus 34% in single cord unit recipients
at 5 years. Brunstein et al. [30] compared donor sour-
ces for HCT performed for hematologic malignancies:
matched sibling donor (MSD), matched unrelated
donor (MUD), mismatched unrelated donor versus
unrelated double umbilical cord (dUCB). All sources
were associated with similar leukemia-free survival
(LFS). However, in the dUBC recipients, the risk of
relapse was much lower with 15%, compared with
MSD (43%), MUD (37%), and mismatched unrelated
donor (35%). Conversely, the nonrelapse mortality
(NRM) was higher (34%) for dUCB compared with
both MRD (24%) and MUD (14%). Currently, there
is an North American open ongoing randomized study
in pediatrics comparing single versus double umbilical
cord blood for hematologic malignancies that will ul-
timately assist in answering this question. Strategies
to reduce the NRM in dUCB recipients may harness
the benefit of utilizing dUCB with respect to an
enhanced GVL effect.
Kller Cell Immunoglobulin-Like Receptor (KIR)
Ligand Incompatibility
Donor KIR-ligand incompatibility in some reports
has been associated with decreased relapse incidence
(RI) and improved LFS after haploidentical, MUD,
and MSD transplantation [31-33]. Scquizzato et al.
[31] analyzed donors KIR genotype and HLA geno-
type of 60 pediatric patients who received related orunrelated HCT for hematologic malignancies. When
patients were grouped based on the KIR genotype
involved in the KIR/HLA-I mismatch, they did not
observe any relapse in the group of patients character-
ized by mismatches involving only inhibitory KIR.
Willemze et al. [34] studied a cohort of 218 patients
that included pediatric patients and showed that
KIR-ligand-incompatible umbilical cord blood trans-
plantations (UCBTs) had improved LFS and OS and
decreased RI [34]. These results were more evident
for AML transplantation recipients (2-year LFS and
RI with or without KIR-ligand incompatibility (73%
versus 38% and 5% versus 36%, respectively). How-
ever, Brunstein et al. [35] found a negative effect of
KIR mismatching in reduced-intensity UCBTs [35].
Therefore, future prospective studies need to be per-
formed. Currently, there is an ongoing Children’s On-
cology Group study evaluating the effect of KIR
mismatching in unrelated donor transplantation for
pediatric AML and MDS.Novel Conditioning Regimens in Pediatrics
Incorporating novel agents in the conditioning
regimen with potent antileukemic activity is a strategy
that is currently under investigation. Treosulfan is an
alkylating agent approved in Europe for the treatment
of ovarian carcinoma [36]. In vitro studies have shown
that treosulfan was more active than busulfan against
pediatric leukemia [37]. In the Mideast, United States,
and Europe, this drug is currently under investigation
as an agent for transplantation conditioning regimens
[38-40]. Most studies have combined treosulfan with
fludarabine. Fludarabine heightens the immune
suppression of the regimen and may also synergize
the effect of the alkylating agent by inhibiting the
repair of DNA. Nemecek et al. [39] performed a phase
I/II study in 60 patients with a median age of 46 years
(range, 5-60 years) and a majority having myeloid
malignancies. Patients received intravenous treosulfan
and fludarabine followed by infusion of marrow or
peripheral blood stem cells from MRD or MUD.
The NRM was 5% and 8% at day 1100 and 2 years
post-HCT, respectively. With a median follow-up of
22 months, the 2-year relapse-free survival for all
patients was 58% and 88% for patients without
high-risk cytogenetics. The treosulfan/fludarabine
regimen was well tolerated and yielded encouraging
survival and low rates ofNRM.A future trial is planned
in the United States through the Pediatric Blood and
Marrow Transplant Consortium utilizing this regi-
men, and a concurrent European trial is underway.
Clofarabine is a novel nucleoside analog that has
potent antileukemic activity. It has shown efficacy in
refractory disease as well as up front scenarios. As a
single agent in phase I and II studies in pediatric pa-
tients with relapsed or refractory ALL and AML, it
Biol Blood Marrow Transplant 18:S62-S73, 2012 S69Monitoring and Preventing AML/MDS Relapse after Transplanthad a 26% to 32% overall response rate [41,42].
Preclinical studies done at the MD Anderson Cancer
Center demonstrated that the combination of
clofarabine and cytarabine results in biochemical
modulation of ARA-CTP and synergistic cell kill.
The combination of clofarabine and cytarabine in a se-
quential manner results in a superior clinical response
than either chemotherapy agent alone.Geyer et al. [43]
combined total-body irridiation (TBI) with clofara-
bine and cytarabine for allogeneic HCT in pediatric
patients with refractory or multiply relapsed leukemia
in a phase I/II study [43]. To date, the phase II portion
of the study is underway, and the early results show the
probability of a 1-year progression-free survival of
57.4%. Andersson et al. [44] reported on clofarabine/
fludarabine/busulfan as an RIC regimen for advanced
MDS and AML in 42 patients, which included chil-
dren [44]. In this high-risk patient population, 20
patients are alive at median survival of 23 months,
which is encouraging early results and warrants further
studies. In the future, utilizing these novel agents for
allogeneic transplantation in pediatric AML/MDS
may help reduce the relapse rate post-HCT, particu-
larly in patients with high-risk features of their disease.
Targeted Immunotherapy Post-HCT
One of the strategies for prevention of relapse of
AML/MDS post-HCT is to use targeted immuno-
therapy as part of the conditioning regimen or post-
HCT.
Gemtuzumab Ozogamicin
Approximately 80% of pediatric AML expresses
CD33. CD33 is absent on pluripotent stem cells and
nonhematologic tissue. Gemtuzumab ozogamicin
(GO), an immunotoxin targeted to CD33, has been as-
sociated with 30% overall response rate in refractory
childhood AML [45]. Cairo et al. [46] performed
a phase I/II trial of GO added to myleoablative condi-
tioning (MAC) and post-RIC-HCT in poor- and
average-risk childhood AML, respectively. GO was
administered on day 214 with busulfan and cyclo-
phosphamide followed by HCT (study A) or following
RIC-HCT (fludarabine and busulfan) more than 60
days post-HCT for two doses 8 weeks apart (study
B). In study A, 12 poor-risk AML patients were treated
with a median age of 3 years. There were no dose-
limiting toxicities (DLT) related to GO. The day
1100 treatment-related mortality was 0%, and the
5-year OS was 50%. In study B, 17 average-risk
AML patients were treated with a median age of 13
years. There were no DLTs related to GO; 1-year
OS was 84%. Therefore, GO is well tolerated follow-
ing both MAC- and RIC-HCT. GOmay be a possible
new agent during conditioning and post-MRD setting
in children with AML undergoing HCT. Unfortu-nately, GO has been removed from the USmarket sec-
ondary to concerns over hepatic toxicities.
Wilms Tumor Antigen
WT1 protein, a nearly universal tumor antigen, is
an immunotherapeutic target because of its established
role in leukemogenesis and superior immunogenic
characteristics [47]. In addition, WT1 expression is
found on leukemic stem cells. Keilholz et al. [48] in-
vestigated the immunogenicity of (WT1)-peptide
vaccination in WT1-expressing AML and MDS in
patients without curative treatment options. Patients
who received the vaccine showed stable disease with
some improvements. In a phase I/II trial, van Tende-
loo et al. [49] investigated the effect of autologous
WT1-dendritic cell vaccination in 17 patients with
AML in remission but at high risk of relapse [49].
They found a clinical and molecular response in nine
of 17 patients. Dendritic cell-based immunotherapy
appeared to correlate with clinical benefit. WT1 vac-
cine is a feasible and potentially an effective strategy
to control residual disease in AML, especially as
a postremission treatment to prevent full relapse.
Currently, there are open, phase I clinical trials of
WT1 vaccination in patients who are to receive an
HCT for leukemia or MDS who have an expected
risk of posttransplantation relapse of .30%. Patients
enrolled will be eligible to have donor-derived WT1
peptide- specific T cells generated before or at the
time of transplantation for immediate use posttrans-
plantation at such time that the patient is found to
have MRD or relapse.PREVENTION OF RELAPSE FOLLOWING
ALLOGENEIC HCT IN ADULT PATIENTS
WITH MYELOID MALIGNANCIES
Paralleling the pediatric population, the incidence
of AML and MDS continues to rise, resulting in an
increased utilization for allogeneic HCT for these
disease entities. Although sharing similar treatment
obstacles as pediatric patients undergoing allogeneic
HCT, there are important differences between the
two groups relative to comorbidities, incidence of
NRM and graft-versus-host disease (GVHD), and dis-
ease biology. These differences affect implementation
and outcomes when similar strategies are used to
prevent relapse in the two groups. This section will
focus on current and future strategies under investiga-
tion to prevent relapse after allogeneic HCT in the
adult population.
Conditioning Regimens
There have long been efforts to decrease posttrans-
plantation relapse rates in adults through intensifica-
tion of conditioning regimen, either by increasing
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tional chemotherapy. One past randomized trial in pa-
tients with AML in first CR that focused on TBI dose
found that the relapse rates were lower after 15.75 Gy
compared with 12 Gy (12% versus 35%, respectively)
[50]. However, NRM was increased with the higher
TBI dose, leading to no improvement in OS. Similar
to the findings with TBI, higher chemotherapy doses
in the preparative regimen have also been shown to
decrease relapse rates. Slattery et al. [51] studied 45 pa-
tients with chronic or accelerated- phase CML who
received a preparative regimen consisting of busulfan
and cyclophosphamide and received transplantations
from HLA-identical related donors to determine the
influence of variations in busulfan plasma concentra-
tion on the rate of relapse. Of 22 patients with
steady-state busulfan levels below the median, seven
developed persistent cytogenetic relapse, and three of
these patients died. In contrast, there were no relapses
in patients with steady-state busulfan levels above the
median.
Attempts in the past to develop improved condi-
tioning regimens with increased antitumor effects
and less toxicity have met with only limited success.
Results with RIC, which are associated with decreased
acuteNRM, have demonstrated increased relapse rates
compared with myeloablative regimens. However,
there are several new agents that demonstrate unique
biologic activity that are under investigation in the
transplantation setting. Farag et al. [52] investigated
the use of clofarabine, a nucleoside-analog with
a high degree of activity in refractory AML, in combi-
nation with busulfan as part of a phase I trial in 15
patients with high-risk acute leukemias. The
maximum-tolerated dose of clofarabine was not
reached. In this high-risk population, the EFS and
OS at 1 year were 53% and 60%, respectively. The
incorporation of histone deacetylase inhibitors and hy-
pomethylating agents, either as part of the condition-
ing regimen or in the early posttransplant setting, is
currently under clinical investigation.
There has also been interest in the use of radioim-
munoconjugates as part of the conditioning regimen.
In patients with advanced AML,MDS, or ALL, a study
of the 131I-anti-CD45 radioimmunocojugate was per-
formed to determine the biodistribution of the tar-
geted radiotherapy and the maximum tolerated dose
of radiation delivered when combined with a myeloa-
blative conditioning regimen consisting of cyclophos-
phamide and TBI [53]. The estimated supplemental
doses of radiation delivered were 24 Gy to bone
marrow and 50 Gy to spleen. In a subsequent trial,
Pagel et al. [54] demonstrated that the 131I-anti-
CD45 radioimmunocojugate can be safely combined
with an RIC regimen in older relapsed or refractory
patients with AML and MDS. In this latter study,
treatment produced a complete remission in allpatients, and chimerism analyses showed 100%
donor-derived CD31 and CD331 cells in the periph-
eral blood by day 128 after transplantation. The esti-
mated probability of recurrent malignancy at 1 year
was 40%, and the 1-year OS was 41%.
Cellular Therapies
Donor leukocyte infusions
The results of donor leukocyte infusions (DLIs) in
patients with relapsed AML and MDS have been rela-
tively disappointing. Administration of chemotherapy
followed by DLIs has been associated with slightly
improved outcomes but is associated with increased
toxicities. Because DLI seems to be most effective
for patients with minimal disease burden, prophylactic
or preemptive DLIs while patients are in hematologic
remission may improve outcomes and reduce toxicity,
primarily GVHD. Schmid et al. [55] investigated the
use of preemptive DLIs in 46 AML patients undergo-
ing allogeneic HCT. DLIs were given at 120 days after
transplantation if patients were off immunosuppres-
sion and there was no active GVHD. Survival was
improved in patients who received preemptive DLIs
compared with case-matched controls.
Natural Killer Cells
Natural killer (NK) cells are capable of lysing
tumor cells without priming. Expression of killer in-
hibitory receptors (KIR) on NK cells permits recogni-
tion of groups of class I HLA alleles and inhibits NK
cytotoxicity. Studies ofNK cell alloreactivity in alloge-
neic HCT from different stem cell sources have shown
the antileukemic effects of donorNK cells, particularly
in the haploidentical transplantation setting [56].
Efforts to adoptively transfer NK cells to prevent
and treat leukemia relapse both after HCT are cur-
rently under investigation.
Maintenance Therapy
Posttransplantation therapy
The role of posttransplantation therapy has been
poorly studied. Most of these approaches have been
limited to TKI in patients with BCR-ABL1-positive
leukemias [57]. However, other strategies including
the use of interleukins, monoclonal antibodies,
immunomodulatory agents (bortezomib), DNAmeth-
yltransferase inhibitors, and histone deacetylase inhib-
itors are currently being explored. The goal of these
approaches is to treat MRD while minimizing adverse
side effects and avoiding the impediment of donor cell
engraftment. The administration of chemotherapy af-
ter HCT remains an open area for exploration.
The use of hypomethylating agents (eg, azaciti-
dine) in patients with MDS has drawn increased
interest because of their demonstrated efficacy and
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[58] conducted a study of the posttransplantation ad-
ministration of azacitidine to determine a safe dose
and schedule combination in 45 patients with high-
risk AML and MDS undergoing allogeneic HCT.
The study looked at different combinations of five
daily azacitidine doses, 8, 16, 24, 32, and 40 mg/m2,
and four schedules: 1, 2, 3, or 4 cycles, each with 5
days of drug and 25 days of rest. Cycle 1 started on
day 140. Reversible thrombocytopenia was the dose-
limiting toxicity, and the investigators determined
that the optimal combination was 32 mg/m2 given
for 4 cycles. No dose significantly affectedDNA global
methylation. One-year EFS and OS were 58% and
77%, respectively.CONCLUSIONS
Although allogeneic HCT is the major option for
long-term survival and potentially cure in patients
with AML and MDS, its efficacy is severely limited
by relapse of disease. As such, disease monitoring
and novel strategies, such as use of novel drugs with
and after the conditioning regimen, cellular therapies,
and vaccines, are necessary [59].
Measurement of BCR-ABL1 in CML provides an
excellent model forMRDmonitoring in the posttrans-
plantation period. In AML andMDS, efforts are made
to transfer already existing MRD markers from the
conservative treatment setting into posttransplanta-
tion surveillance, but for many patients with AML
and for most with MDS, chimerism, peripheral blood
parameters, and bonemarrow cytomorphology remain
the only options for disease detection post-HCT. The
recent increase of the molecular marker spectrum (eg,
RUNX1 or TET2) in patients with AML and MDS
offers new options for posttransplantationMRDmon-
itoring [60]. Their incorporation in MRD studies
might be facilitated by the novel high-throughput
sequencing methods, as recently shown with regard
to RUNX1-mutated AML and MDS. Beyond the ex-
pansion of the spectrum of molecular MRD markers
and methods, transplantation research should try to
define cutoff MRD levels for the distinct molecular
markers and determine the time points best suitable
for investigation as a guideline for therapeutic strate-
gies in the posttransplantation period.
Several novel strategies to reduce the relapse rate
post-HCT are currently under investigation for both
pediatric and adult myeloid malignancies. These
include identification of high-risk patients by MRD,
optimizing graft sources for augmentation of a GVL
effect, novel conditioning regimens, and immunother-
apy post-HCT.Hopefully with one of these approaches
or a combination of them, we will see a reduction of the
relapse rate post-HCT in the near future.ACKNOWLEDGMENTS
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